anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Metric

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 79,264
Current window 72,601-72,630
Pages 2,643
Rows per page 30
Component: Metricclear collectionreset all
18 30 60

Component

72,601-72,630 of 79,264

filter-aware
07
The slide uses a table to demonstrate the increasing reliance on the Chinese market.Herbalife, Ltd. (HLF) · William Ackman
Activist deck Activist investor Beat · The Monster1 hit
18
This slide is likely from an activist presentation (Pershing Square/Ackman) critiquing Herbalife's business model by highlighting how 'credits' are framed as 'salary'.Herbalife, Ltd. (HLF) · William Ackman
Activist deck Activist investor Beat · The Monster1 hit
19
The slide highlights the structural incentive for recruiting inherent in the compensation model.Herbalife, Ltd. (HLF) · William Ackman
Activist deck Activist investor Beat · The Monster1 hit
42
The slide uses a table from the 2013 10K to demonstrate that China's contribution margin is artificially inflated compared to other regions.Herbalife, Ltd. (HLF) · William Ackman
Activist deck Activist investor Beat · The Victory1 hit
43
The slide uses a table to perform a pro forma adjustment on contribution margins, highlighting the discrepancy between reported and adjusted figures.Herbalife, Ltd. (HLF) · William Ackman
Activist deck Activist investor Beat · The Victory1 hit
44
The slide uses a screenshot of a spreadsheet to provide primary source evidence of internal financial assumptions.Herbalife, Ltd. (HLF) · William Ackman
Activist deck Activist investor Beat · The Victory1 hit
45
The slide uses a red box to highlight the matching figures between the internal document and the public 10-K filing.Herbalife, Ltd. (HLF) · William Ackman
Activist deck Activist investor Beat · The Victory1 hit
47
The slide uses an internal document to expose the mechanical nature of their financial forecasting, specifically targeting the 'China Sales Employees' line item.Herbalife, Ltd. (HLF) · William Ackman
Activist deck Activist investor Beat · The Victory1 hit
48
The slide uses a stacked bar chart to visualize the components of distributor payout, contrasting retail profit with various bonuses.Herbalife, Ltd. (HLF) · William Ackman
Activist deck Activist investor Beat · The Victory1 hit
49
The slide uses a red arrow to link a table of percentages to a visual breakdown of the 73% distributor payout.Herbalife, Ltd. (HLF) · William Ackman
Activist deck Activist investor Beat · The Victory1 hit
04
This slide serves as a company profile/introductory slide for an activist investor deck.Valeant Pharmaceuticals International (VRX) · William Ackman
Activist deck Activist investor Beat · Setup1 hit
07
The chart uses callout boxes to link specific dates and events to the share price trajectory.Valeant Pharmaceuticals International (VRX) · William Ackman
Activist deck Activist investor Beat · Complication1 hit
08
The slide uses a line chart with callout boxes to correlate specific news events with stock price volatility.Valeant Pharmaceuticals International (VRX) · William Ackman
Activist deck Activist investor Beat · Complication1 hit
09
Uses a timeline-annotated line chart to frame market volatility as a series of events to be addressed.Valeant Pharmaceuticals International (VRX) · William Ackman
Activist deck Activist investor Beat · Complication1 hit
11
This slide is part of a series exposing the Valeant-Philidor relationship.Valeant Pharmaceuticals International (VRX) · William Ackman
Activist deck Activist investor Beat · Evidence1 hit
20
The table serves as a precedent for regulatory risk and financial impact in the pharmaceutical industry.Valeant Pharmaceuticals International (VRX) · William Ackman
Activist deck Activist investor Beat · Preempt Rebuttal1 hit
21
The slide uses a 'villain' framing by contrasting the high penalties of established peers against the absence of the target company (Valeant).Valeant Pharmaceuticals International (VRX) · William Ackman
Activist deck Activist investor Beat · Preempt Rebuttal1 hit
30
Valeant Pharmaceuticals International (VRX)Valeant Pharmaceuticals International (VRX) · William Ackman
Activist deck Activist investor Beat · Resolution1 hit
30
The slide uses a 10% discount rate for PV calculations and assumes a constant 16x NTM P/E multiple.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor Beat · Solution1 hit
31
Includes disclaimer regarding valuation assumptions and data sources.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
32
Valeant Pharmaceuticals International (VRX)Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
37
The slide uses specific financial metrics (EBITA, Gross Margin, Forward EPS) to establish a peer benchmark for Valeant's portfolio durability.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
38
The table includes a calculated average row at the bottom.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
40
The slide justifies using non-healthcare benchmarks for valuation by highlighting similar margin and growth profiles.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
41
The slide uses a bar chart to establish a valuation benchmark for non-healthcare sectors.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
42
The chart uses a box-plot style to show ranges for different comparable categories.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
43
Valeant Pharmaceuticals International (VRX)Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
44
The slide uses a bridge framework to reconcile 2015 revenue to 2020 estimates for cliff products.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
45
The slide provides specific financial modeling parameters for Valeant and Salix, excluding future acquisitions.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
46
The slide details specific financial ratios (90% conversion, 4x leverage target, 5.75% cost of debt) and compares them to current/transaction-specific metrics.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit